Sun Xinghuai, Lin Mingkai, Duan Xuanchu, Zhang Chun, Ming Jian
Eye, Ear, Nose and Throat Hospital, Shanghai Medical College, Fudan University, Shanghai.
Key Laboratory of Myopia, Ministry of Health (Fudan University), and Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University), Shanghai.
Patient Prefer Adherence. 2017 Apr 28;11:845-852. doi: 10.2147/PPA.S131853. eCollection 2017.
Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients' satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC).
This observational, multicenter study was conducted in China in adults with glaucoma treated with BTFC for 1-3 months. Five hundred patients answered a questionnaire concerning their demographic characteristics, history of glaucoma and topical glaucoma treatment, and use of BTFC. The primary endpoint was patient satisfaction with BTFC assessed on a 10-point scale (1= very dissatisfied, 10= very satisfied).
Patients received BTFC alone (65%) or with other treatments (35%), most commonly a carbonic anhydrase inhibitor. Most patients (87%) used BTFC as a replacement for other medication, usually a β-blocker or prostaglandin analog; 13% received BTFC as add-on treatment. Key reasons for initiating BTFC therapy were poor efficacy of previous treatment (72% of patients) and side effects of previous treatment (32% of patients). Most patients agreed or very much agreed that BTFC provided better control of intraocular pressure (85% of patients), had a simpler administration (87% of patients), and was associated with better tolerance and comfort (82% of patients) compared with their previous treatment. Mean satisfaction scores were significantly higher for BTFC than for previous treatments among all patients (7.8 versus 6.0; <0.0001) and within patient subgroups based on demographic characteristics, pattern of BTFC use, and previous treatment.
Patients were highly satisfied with BTFC used alone or concomitantly with another topical medication. Patients previously treated with a β-blocker, prostaglandin analog, carbonic anhydrase inhibitor, α-adrenergic agonist, or combination of two medications were more satisfied with BTFC than with their previous treatment. Most reported that intraocular pressure control, tolerability, and ease of administration improved with BTFC.
青光眼治疗中治疗依从性差是一个问题，而患者对局部使用的青光眼药物不满意是依从性的一个障碍。本研究的目的是评估青光眼患者对固定复方比马前列素/噻吗洛尔滴眼液（BTFC）的满意度。
这项观察性多中心研究在中国进行，纳入使用BTFC治疗1至3个月的成年青光眼患者。500名患者回答了一份关于其人口统计学特征、青光眼病史和局部青光眼治疗情况以及BTFC使用情况的问卷。主要终点是通过10分制评估患者对BTFC的满意度（1=非常不满意，10=非常满意）。
患者单独使用BTFC（65%）或与其他治疗联合使用（35%），最常见的联合用药是碳酸酐酶抑制剂。大多数患者（87%）使用BTFC替代其他药物，通常是β受体阻滞剂或前列腺素类似物；13%的患者接受BTFC作为附加治疗。开始BTFC治疗的主要原因是先前治疗效果不佳（72%的患者）和先前治疗的副作用（32%的患者）。大多数患者同意或非常同意，与先前治疗相比，BTFC能更好地控制眼压（85%的患者）、给药更简单（87%的患者），并且耐受性和舒适度更好（82%的患者）。在所有患者中（7.8对6.0；<0.0001）以及在基于人口统计学特征、BTFC使用模式和先前治疗的患者亚组中，BTFC的平均满意度得分显著高于先前治疗。
患者对单独使用或与另一种局部药物联合使用的BTFC高度满意。先前接受β受体阻滞剂、前列腺素类似物、碳酸酐酶抑制剂、α肾上腺素能激动剂或两种药物联合治疗的患者对BTFC的满意度高于先前治疗。大多数患者报告称，BTFC改善了眼压控制、耐受性和给药便利性。
